1,3-二甲基戊胺

1,3-二甲基戊胺
臨床資料
其他名稱	1,3-二甲基戊胺; 1,3-DMAA; 二甲基戊胺; DMAA
給藥途徑	鼻內噴劑（英語：nasal spray）、口服
ATC碼	未分配;
藥物動力學數據
生物半衰期	~8.5小時
辨識資訊
	IUPAC命名法 4-Methylhexan-2-amine; ;
CAS號	105-41-9
PubChem CID	7753;
ChemSpider	7467 ;
UNII	X49C572YQO;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID60861715 ;
ECHA InfoCard	100.002.997
化學資訊
化學式	C7H17N
摩爾品質	115.22 g·mol−1
3D模型（JSmol（英語：JSmol））	互動式圖像;
	SMILES CCC(C)CC(C)N;
	InChI InChI=1S/C7H17N/c1-4-6(2)5-7(3)8/h6-7H,4-5,8H2,1-3H3 ; Key:YAHRDLICUYEDAU-UHFFFAOYSA-N ;

甲基己胺（又稱1,3-二甲基戊胺、1,3-DMAA、二甲基戊胺和DMAA；商品名Forthane和Geranamine）是一種由禮來公司發明並研發的間接擬交感神經藥，自1948年以來作為一種吸入型鼻塞緩解劑（英語：nasal decongestant）投放市場，但於1970年代被停止銷售。^[2]

自2006年以來，甲基己胺以許多名稱作為興奮劑或提高能量的補劑廣泛銷售，據說是因為它類似於老鸛草中的某些化合物，但因具有數個不良副作用而受到質疑，至少有五個死亡與含甲基己胺的補劑有關。^[3]它被許多運動管理局和政府機構禁止。即使FDA已發出幾封警告信，^[4]截至2019年，這種化合物仍出現於運動和減肥補劑中。^[5]

參見

參考文獻

^ 1,3-Dimethylpentylamine - Compound Summary. PubChem Compound. USA: National Center for Biotechnology Information. Identification and Related Records. 26 March 2005 [27 May 2012]. （原始內容存檔於2014-03-01）.
^ Cohen, Pieter A. DMAA as a Dietary Supplement Ingredient. Archives of Internal Medicine. 9 July 2012, 172 (13): 1038–9. PMID 22566490. doi:10.1001/archinternmed.2012.1677 .
^ Singer, Natasha; Peter Lattman. F.D.A. Issues Warning on Workout Supplement. New York Times. April 16, 2013 [April 16, 2013]. （原始內容存檔於2019-01-03）.
^ FDA, Center for Food Safety and Applied. Products & Ingredients - DMAA in Products Marketed as Dietary Supplements. FDA. May 2019 [2022-02-22]. （原始內容存檔於2019-04-23）（英語）.
^ Cohen, Pieter A.; Wen, Anita; Gerona, Roy. Prohibited Stimulants in Dietary Supplements After Enforcement Action by the US Food and Drug Administration. JAMA Internal Medicine. 1 December 2018, 178 (12): 1721–1723. PMC 6583602 . PMID 30422217. doi:10.1001/jamainternmed.2018.4846.

外部連結

Stimulant Potentially Dangerous to Health, FDA Warns. U.S. Food and Drug Administration. April 11, 2013 [2022-02-22]. （原始內容存檔於2014-02-01）.
Bussel, Igor I; Pavlov Jr, Andrey A. DMAA: Efficacious but is it Safe?. Science Based Medicine Blog. June 7, 2013 [2022-02-22]. （原始內容存檔於2013-06-09）.

[1] 1,3-Dimethylpentylamine - Compound Summary. PubChem Compound. USA: National Center for Biotechnology Information. Identification and Related Records. 26 March 2005 [27 May 2012]. （原始內容存檔於2014-03-01）.

[2] Cohen, Pieter A. DMAA as a Dietary Supplement Ingredient. Archives of Internal Medicine. 9 July 2012, 172 (13): 1038–9. PMID 22566490. doi:10.1001/archinternmed.2012.1677 .

[nyt-fda-3] Singer, Natasha; Peter Lattman. F.D.A. Issues Warning on Workout Supplement. New York Times. April 16, 2013 [April 16, 2013]. （原始內容存檔於2019-01-03）.

[4] FDA, Center for Food Safety and Applied. Products & Ingredients - DMAA in Products Marketed as Dietary Supplements. FDA. May 2019 [2022-02-22]. （原始內容存檔於2019-04-23）（英語）.

[5] Cohen, Pieter A.; Wen, Anita; Gerona, Roy. Prohibited Stimulants in Dietary Supplements After Enforcement Action by the US Food and Drug Administration. JAMA Internal Medicine. 1 December 2018, 178 (12): 1721–1723. PMC 6583602 . PMID 30422217. doi:10.1001/jamainternmed.2018.4846.

[1]

[2]

[3]

[4]

[5]